Overexpression of IL-13Rα2 has been described in oncological pathologies like glioblastoma, adrenocortical carcinoma, head and neck cancer, melanoma, ovarian cancer, and pancreatic cancer [34], where anti-inflammatory and immunosuppressor environments are necessary for tumor survival; the M2-Th2 microenvironment in oncological pathologies is similar to that observed in helminth infections. Here, IL13RA2 is linked to melanoma.